Results 51 to 60 of about 2,336 (164)
Recombinant production platform for Group A Streptococcus glycoconjugate vaccines
Group A Streptococcus (Strep A) is a human-exclusive bacterial pathogen killing annually more than 500,000 patients, and no current licensed vaccine exists.
Sowmya Ajay Castro +16 more
doaj +1 more source
Invasive infections associated with non-typhoidal Salmonella (NTS) serovars Enteritidis (SE), Typhimurium (STm) and monophasic variant 1,4,[5],12:i:- are a major health problem in infants and young children in sub-Saharan Africa, and currently, there are
Scott M Baliban +16 more
doaj +1 more source
Background Worldwide, an estimated 70.7 billion broilers were produced in 2020. With the reduction in use of prophylactic antibiotics as a result of consumer pressure and regulatory oversight alternative approaches, such as vaccination, are required to ...
Alexander A. Smith +5 more
doaj +1 more source
Recent advances in the production of recombinant glycoconjugate vaccines [PDF]
AbstractGlycoconjugate vaccines against bacteria are one of the success stories of modern medicine and have led to a significant reduction in the global occurrence of bacterial meningitis and pneumonia. Glycoconjugate vaccines are produced by covalently linking a bacterial polysaccharide (usually capsule, or more recently O-antigen), to a carrier ...
Emily Kay, Jon Cuccui, Brendan W. Wren
openaire +3 more sources
ABSTRACT While targeted therapies have improved outcomes in lung adenocarcinoma (LUAD), many patients still lack targetable mutations. Here, we identified alpha‐L‐fucosidase 2 (FUCA2) as a crucial driver of LUAD by preventing cellular senescence. Mechanistically, through the restriction of fucosyltransferase 3 (FUT3)‐mediated α‐1,3‐fucosylation of ...
Lu Chen +18 more
wiley +1 more source
Glycoconjugation is a well-established technology for vaccine development: linkage of the polysaccharide (PS) antigen to an appropriate carrier protein overcomes the limitations of PS T-independent antigens, making them effective in infants and providing
Rebecca Nappini +11 more
doaj +1 more source
H‐bond‐mediated aglycone delivery method has been applied to the synthesis of glucosamine glycosides. ABSTRACT Controlling stereoselectivity of glycosylation reactions remains one of the central challenges in synthetic carbohydrate chemistry. In this study, we explore the impact of O‐picoloyl (Pico) protecting group positioning on the stereoselectivity
Alessandra Damico +2 more
wiley +1 more source
Micellar systems based on biodegradable aliphatic polycarbonates and acid‐responsive triggers enhance drug solubility, stability, and tumor‐selective release. This review covers micelles with acid‐cleavable drug linkages and those that disassemble via acid‐sensitive functionalities.
Adrian V. Hauck, Lutz Nuhn
wiley +1 more source
Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives
Schematic illustration of four emerging CRISPR–Cas delivery platforms defined by distinct design principles and structural features: virus‐mimicking nanosystems (e.g., VLPs), cell‐derived extracellular vesicles, cell‐penetrating peptides, and stimuli‐responsive scaffolds. These platforms enable spatiotemporally controlled delivery of RNPs, mRNA, or DNA
Meijia Yang +9 more
wiley +1 more source
Substrate scope of ancestral versus modern family‐1 glycosidases
Abstract Experimental studies support that protein engineering based on ancestral sequence reconstruction often leads to variants with biotechnologically useful biomolecular properties. These may include high stability, enhanced conformational flexibility and a modified catalysis range.
Luis I. Gutierrez‐Rus +11 more
wiley +1 more source

